ArticleDiscover oncology2026
Novel cuproptosis related long non-coding RNA signature in oral squamous cell carcinoma prognosis and immunotherapy.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Cuproptosis, a recently identified copper-dependent regulated cell death, is increasingly recognized for its relevance in cancer biology. In their study, Kong L et al. have developed a four long non-coding RNA (lncRNA) cuproptosis-related prognostic signature that effectively stratifies oral squamous cell carcinoma (OSCC) patients. The study reveals distinct immune microenvironment patterns with implications for immunotherapy response. Their experimental validation of STARD4-AS1 further supports biological relevance. This comment underscores the importance of integrating cuproptosis biology with lncRNA profiling to enhance prognostic accuracy and inform therapeutic strategies in OSCC. It also emphasizes the need for external validation and detailed mechanistic studies to support clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.